Literature DB >> 19106348

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Michael Rybak1, Ben Lomaestro, John C Rotschafer, Robert Moellering, William Craig, Marianne Billeter, Joseph R Dalovisio, Donald P Levine.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19106348     DOI: 10.2146/ajhp080434

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  432 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

3.  Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Authors:  Anthony M Nicasio; Jürgen B Bulitta; Thomas P Lodise; Rebecca E D'Hondt; Robert Kulawy; Arnold Louie; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

4.  Pediatric pharmacokinetics of vancomycin: a canadian perspective.

Authors:  Anais Delicourt; Jean-François Bussières; Denis Lebel
Journal:  Can J Hosp Pharm       Date:  2011-03

5.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

Review 6.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

7.  Impact of Pharmacy Practice Model Expansion on Pharmacokinetic Services: Optimization of Vancomycin Dosing and Improved Patient Safety.

Authors:  Zhe Han; Natasha N Pettit; Emily M Landon; Benjamin D Brielmaier
Journal:  Hosp Pharm       Date:  2017-04

8.  The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.

Authors:  Sarah Stevenson; Wen Tang; Yeoungjee Cho; David W Mudge; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

9.  Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.

Authors:  Calvin L Miller; S Alexander Winans; John J Veillette; Steven C Forland
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

10.  Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Authors:  Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.